CD276-directed supramolecular nanoplatform with pH-triggered gemcitabine release for potent tumor stromal and vascular suppression.

ABSTRACT: Gemcitabine (Gem) remains a cornerstone chemotherapy for pancreatic ductal adenocarcinoma, but its clinical efficacy is limited by poor pharmacokinetics, dense fibrotic stroma, and hypovascularization. While pH-responsive liposomes can enhance circulation and targeted drug release, their clinical application is hindered by low drug loading capacity and premature leakage of hydrophilic drugs. To address these challenges, we exploited the high and specific expression of CD276 on pancreatic cancer cells, tumor vasculature, and fibroblasts. We engineered a high-specificity and high-affinity anti-CD276 scFv, and developed a novel nanoplatform (Gem@CPL) that integrates pH-responsive and supramolecular assembly strategies with Gem, achieving 4-fold higher drug loading, improved stability, and tum

SUBMITTER: Li J 

PROVIDER: S-EPMC12681842 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature